Related Experiment Video
Updated: May 22, 2026
08:26
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS
S E Bushnell1, Z Zhao, C C Stebbins
1Biogen Idec, Cambridge, MA, USA. steven.bushnell@biogenidec.com
Neurology
|May 11, 2012
Summary
This study could not validate that serum interleukin-17F predicts poor response to interferon-beta therapy in relapsing-remitting multiple sclerosis patients. Further research is needed to find reliable biomarkers for treatment response.
Area of Science:
- Neuroimmunology
- Biomarker Discovery
Background:
- Relapsing-remitting multiple sclerosis (RRMS) requires biomarkers to predict treatment response to disease-modifying therapies.
- Previous research suggested serum interleukin (IL)-17F levels might predict poor response to interferon-beta (IFNβ).
Purpose of the Study:
- To validate whether pretreatment serum IL-17F levels predict poor response to IFNβ therapy in a large, independent cohort of RRMS patients.
Main Methods:
- Serum samples from 118 RRMS patients (54 good responders, 64 poor responders) from a clinical trial were analyzed for IL-17F.
- Patients were classified as good or poor responders based on clinical and MRI outcomes.
- Assays included multiplexed Luminex and ELISA; replicate samples from prior study were also tested.
Main Results:
- No statistically significant difference in median pretreatment or post-treatment serum IL-17F levels was observed between good and poor responders.
- Serum IL-17F/IL-7 ratios did not predict response status.
- Replicate samples from the original Stanford study showed good correlation, confirming assay reproducibility.
Conclusions:
- The study failed to validate serum IL-17F as a predictor of poor response to IFNβ in RRMS.
- Discrepancies may be due to differences in patient populations or methodologies between studies.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...